	adapalene concentration	32.5887859280677
	weight adapalene	32.1415741105888
	topical adapalene composition	22.940905350439774
	earlier launch adapalene product	12.059701096497937
	acne treatment	8.139683981190739
	Adapalene Gel	6.983920809865338
¡°	topical acne medication	5.234584562403044
	Dermatol	5.0358434469645825
	Verschoore	4.2700993723518375
	Acne Vulgaris	3.9176946269822026
	known retinoid	3.6494376739566046
	Gels	3.360556253145409
¡°	prior art Differin	3.0585551181175736
¡°	Differin (r) gel	3.041263425833932
	poloxamer	2.801389420083149
	sole anti acne ingredient	2.723384629753608
	Topical Retinoids	2.5205113289396914
	ANDA product	2.399271857819365
	dermatologist	2.2418528899140657
	Photodamage Skin	2.0776066225245224
	Bershad	1.9596769386555986
	Allec	1.8645121213501132
	Data Sheet	1.8435337470160347
	intolerable irritability	1.684147030136581
	Venerol	1.6819461734593786
	Topical Treatment	1.6177433496651201
	tolerance	1.5759756701297338
	Acad	1.5759756701297338
	Low Skin Irritation Potential	1.5720458574948708
	topical medication	1.5672422224252556
	New Topical Retinoid	1.260553503724965
	cream	1.121668780568186
	Venereol	1.121668780568186
	Actinic Keratoses	1.121668780568186
	Aging	1.121668780568186
	Effectiveness	0.8409730867296893
	Jamoulle et al	0.7777873013795645
	comparable tolerability	0.6958227235920506
	Comparative Study	0.6888700189412338
	S.N.C.	0.5610202201154547
	Budde	0.5610202201154547
	tripling	0.5606499353020366
	DePuy Spine	0.4944003950020932
	specific inactive ingredient	0.4688848519120025
	vary concentration	0.45036695640227975
	multiple concentration	0.44961890495499385
	various concentration	0.4491840414554269
	least one carbomer gel agent	0.39155849921139074
	Goldfarb Abstract	0.37438933877742414
	one inactive excipient	0.37220795702779064
	Unexpected result	0.33817312571449076
	topically applicable pharmaceutically acceptable aqueous gel comprising	0.3338662325089779
	OBVIOUSNESS	0.3236112963431055
	J.T. Eaton	0.307504509166987
	standard optimal concentration	0.306379493991842
	concentration range	0.30274376212235404
	supp.3	0.28051011005772736
	Vehicle	0.2255867280755324
	promotional expenditure	0.2213711177099982
	topically applicable pharmaceutical composition	0.2056526512076214
	C. Commercial Success	0.18866936232644718
	Fulton	0.17095291589919281
	Aller	0.17095291589919281
	Supp	0.15979412883857452
	topically applicable pharmaceutically acceptable medium therefor	0.1378553254727926
	Soni	0.13593968781528526
	Col.	0.12723964458025525
	small percentage	0.12334886373122002
	another ANDA filer	0.11765498213630406
	concomitant increase	0.11516574175567806
	patent.1	0.11157474686297711
	avowed purpose	0.10787951340154807
	cosmetic composition	0.10154919256464102
	investigation	0.0937955201634465
	Winner	0.09366586382920182
	undisturbe district court finding	0.09351415896631865
	increase efficacy	0.08749936661823332
	Effects	0.08547645794959641
	a. Patented Technology	0.06219538645007878
	dose dependent increase	0.061806295614306714
	unexpected result	0.058418369752288625
	several exemplary formulation	0.05691914653909574
	clinically significant increase	0.052901895501840795
	Development	0.047452916004599284
	dose dependent side effect	0.04675103181790588
	unexpected increase	0.04622948835347657
	inventive compound	0.045183326564174155
	Wang	0.042441318596424776
	expiration	0.03901927547624298
	L.P.	0.038489022988635234
	Align Tech	0.03576134629864881
	Hatch Waxman case	0.03416567338109337
	kind	0.0319664042612376
	animal model	0.030569208375477035
	i4i Ltd. p'ship	0.029973002171894386
	Harris	0.028490207442033354
	FDA Orange Book	0.02818747739872688
	Medtronic Sofamor Danek Inc.	0.027933540909064226
	competition	0.02603008688607845
	USA Sports Inc.	0.022257617037067728
	author	0.022227827502706837
	reaction time	0.02066879124841426
	unsolved need	0.019084315433030855
	temperature	0.018634487638917722
	Delaware	0.018309281548055483
	approval	0.017804872383449556
	market share	0.016702310611710486
	brand drug	0.01618894619670579
	generic drug manufacturer	0.013071941978308854
	percent increase	0.013017980407210895
	Nothing	0.01283817549565265
	generic pharmaceutical company	0.012298657176464944
	production	0.012095878124219996
	degree	0.011312663632752455
	prior art article	0.010420508146963603
	seven composition example	0.010190209111960351
	increase side effect	0.010100611493386652
	many skilled artisan	0.009779762367510655
	ii	0.009157674121091844
	nonobviousness	0.008774948164499537
	general preference	0.008722602708120338
	old compound	0.008198880900542355
	Microsoft Corp.	0.007986739936789231
	preferred range	0.007685565979795325
	BACKGROUND	0.007274227666361923
	improve yield	0.006104048916897219
	series	0.005985400360386637
	asserted commercial success	0.005482535436395012
	generic version	0.005436088269856188
	total weight	0.004974531131803946
	know compound	0.004878668819721915
	KSR	0.004705939713990714
	successful product	0.004563094079787308
	overall decline market	0.004476354550565659
	analogous structure	0.00407183356722963
	Abbreviated New Drug Application	0.003837977559190988
	J.A.	0.0037769217646919408
	pertinent secondary consideration	0.003655921475581698
	precise teaching	0.003469259879695156
	disclose range	0.0033608045707830374
	relevant secondary consideration	0.003293267101737105
	certain side effect	0.0028654265267165045
	relevant market	0.0027408777004619624
	neither particular motivation	0.002667472806438249
	least two secondary consideration	0.0026483503082127555
	prior art commercial embodiment	0.0021332451068550055
	amend complaint	0.0020798854635088434
	expect result	0.0018050610499043152
	Teleflex Inc.	0.001780615237924935
	sole dispute	0.001634664965331999
	product insert	0.0015171810488667297
	ultimate burden	0.0014917848202487252
	significant sale	0.0014081653281169605
	instance	0.0012598081396553678
	three piece	0.0012361162904201803
	bench trial	0.0011484574413115841
	a. teaching	0.0010274891348123595
	express teaching	0.0010274891348123595
	obviousness rest	0.0009140040713921092
	effective filing date	0.0007168538332727954
	content	0.0006268220047061509
	January	0.0005985404511678167
	clear convincing evidence	0.0005085633366702738
	objective reach	0.0004735640053943429
	patented invention	0.000397129252445763
	difference	0.00038281965414315865
	nothing	0.00037677377029494654
	mere fact	0.00036150055257932865
	factual consideration	0.0003605950953845968
	obviousness inquiry	0.00032894188188251045
	failure	0.0003223897240250114
	prior art teaching	0.00031252638404327107
	invalidity	0.0002132381272685126
	alternative invention	0.00020963407524761334
	patentee control	0.00018449154314323292
	citation	0.00016988120473431035
	obviousness argument	0.00016803400965338384
	obviousness case	0.00016781275747328186
	defendant	0.0001530229413565999
	underlie fact	0.00012380281260259289
	reverse order	0.00010886290613138767
	respect	9.402104776250168e-05
	district court obviousness analysis	8.747603440969311e-05
	addition	5.8907805541966956e-05
	ordinary skill	5.676510890135494e-05
	background	5.38292409703016e-05
	method	4.0053258781596105e-05
	view	3.172063404197042e-05
	several issue	3.0017146509598792e-05
	clear error	2.9062491697102478e-05
	district court factual finding	2.0593820739105985e-05
	law de novo	1.8920660938657088e-05
	legal conclusion	1.484856925142332e-05
	specification	1.1530404918732504e-05
	district court holding	1.1069490589287307e-05
	know purpose	1.100025134939251e-05
	Claim	8.588968330783008e-06
	prior art result	8.550846563928873e-06
	relevant dispute	5.517844263342089e-06
	Idaho	4.833009576070769e-06
	element	4.754374639326531e-06
	two reason	3.610455138604536e-06
	relevant evidence	2.7455419818497836e-06
	determination	2.147776694535794e-06
	subject matter	1.011733546020237e-06
	light	4.62456101073406e-07
	even use	4.0722872368672963e-07
	prior art reference	3.235042842570839e-07
	record evidence	2.892762036587736e-07
	case law	1.196191178905922e-07
	infringement action	4.130706751691347e-08
	infringement case	9.511352254390437e-09
	U.S.	2.397707610990276e-09
	District	0.0
	Court	0.0
	Appeals	0.0
	Fed	0.0
